Extramedullary manifestations of myeloid neoplasms
CS Wilson, LJ Medeiros - American Journal of Clinical …, 2015 - academic.oup.com
CS Wilson, LJ Medeiros
American Journal of Clinical Pathology, 2015•academic.oup.comObjectives: This session of the 2013 Society of Hematopathology/European Association for
Haematopathology workshop focused on extramedullary manifestations of myeloid
neoplasms. Methods: We divided the submitted cases into four subgroups:(1) isolated
myeloid sarcoma (MS);(2) MS with concurrent acute myeloid leukemia (AML), with a focus
on karyotypic and molecular findings;(3) extramedullary relapse of AML, including relapse in
the posttransplant setting; and (4) blast phase/transformation of a myeloproliferative …
Haematopathology workshop focused on extramedullary manifestations of myeloid
neoplasms. Methods: We divided the submitted cases into four subgroups:(1) isolated
myeloid sarcoma (MS);(2) MS with concurrent acute myeloid leukemia (AML), with a focus
on karyotypic and molecular findings;(3) extramedullary relapse of AML, including relapse in
the posttransplant setting; and (4) blast phase/transformation of a myeloproliferative …
Objectives
This session of the 2013 Society of Hematopathology/European Association for Haematopathology workshop focused on extramedullary manifestations of myeloid neoplasms.
Methods
We divided the submitted cases into four subgroups: (1) isolated myeloid sarcoma (MS); (2) MS with concurrent acute myeloid leukemia (AML), with a focus on karyotypic and molecular findings; (3) extramedullary relapse of AML, including relapse in the posttransplant setting; and (4) blast phase/transformation of a myeloproliferative neoplasm or chronic myelomonocytic leukemia.
Results
Establishing a diagnosis of isolated MS requires a high index of suspicion and use of immunophenotypic methods. Recurrent cytogenetic abnormalities or gene mutations that occur in MS mirror those known to occur in AML.
Conclusions
In the era of targeted therapy and sophisticated risk stratification, every attempt must be made to perform a complete workup on MS cases (or concurrent AML) since the diagnosis of MS, in itself, is no longer adequate for patient management. Cases of blastic plasmacytoid dendritic cell neoplasm were also included and discussed in this session.
Oxford University Press以上显示的是最相近的搜索结果。 查看全部搜索结果